Kilitch Drugs (India) Limited (NSE:KILITCH)

Market Cap	5.49B
Revenue (ttm)	1.82B
Net Income (ttm)	195.12M
Shares Out	n/a
EPS (ttm)	12.14
PE Ratio	28.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,232
Average Volume	12,314
Open	359.95
Previous Close	354.70
Day's Range	340.00 - 369.95
52-Week Range	299.95 - 404.95
Beta	-0.06
RSI	51.92
Earnings Date	May 26, 2025

About Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, antifungals, corticosteroids, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, oncology, ophthalmic, and other drugs, as well as vaccines and veterina...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 168
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KILITCH

Financial Performance

In 2023, Kilitch Drugs (India)'s revenue was 1.54 billion, an increase of 10.58% compared to the previous year's 1.40 billion. Earnings were 146.01 million, an increase of 39.75%.